Investment
Features
FeesSafety
Academy
More
Pluang+

Shares of Hyperliquid Strategies jump 8% after SEC allows tokenized U.S. equity trading on public blockchains

Market News
18 Sep 2026
Blockonomi
View Source
Bullish
Shares of Hyperliquid Strategies jump 8% after SEC allows tokenized U.S. equity trading on public blockchains

Hyperliquid Strategies (PURR) shares rose about 8% following the SEC's announcement of a five-year 'Innovation Exemption' that permits tokenized U.S. stock trading on public blockchain networks via automated market makers. This regulatory relief requires tokenized equities to maintain the same shareholder rights as traditional stocks and mandates transparent, auditable smart contracts on permissionless blockchains. The move is seen as a step toward modernizing U.S. capital markets and aligns well with Hyperliquid's decentralized exchange model, boosting investor confidence. Analysts maintain a unanimous Buy rating on PURR with an average price target of $19.80, while the company’s upcoming earnings report is expected in November 2026.

Hyperliquid Strategies (PURR) stock surged 8% after the SEC approved blockchain trading for tokenized U.S. stocks. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 18, 2026 19:01 WIB: 46 of 50 major cryptocurrencies rose today. Notable movers include BCH at Rp4.390.291 (+10.50%, 6% Sell / 94% Buy), SUSHI at Rp4.380 (+10.39%, 83% Sell / 17% Buy), and DOT at Rp19.927 (+9.80%, 25% Sell / 75% Buy).

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
34 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
48 minutes ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
1 hour ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
2 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App